Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4012 participants.
Also called NCT01938248
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 4,012 participants
- Sponsor
- Registry
-
NCT01938248 -
2014-001397-33
-
- Other papers using this trial's data
- Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
- Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial
- Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA
- Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
- Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01938248. Randomized; quadruple masking; primary purpose prevention. Start 2015-05 (actual); primary completion 2023-10-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
- Acronym
- ARTESiA
- Condition
- Atrial Fibrillation
- Condition
- Stroke
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- aspirin
- Lead sponsor
- Population Health Research Institute
- Collaborator
- Bristol-Myers Squibb
- Collaborator
- Pfizer
- Collaborator
- Medtronic
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct01938248- Content hash
0f6b690d60fcd9461641bd2ab246cd486b9aa68d06f6bfa84fa8dfc034480dfe